Why Vision Loss Lawsuits Often Surface Years After a Drug Reaches the Market

When a prescription drug first comes onto the market, most people assume that all of its serious risks are already known. After all, medications go through years of testing and must be approved by the FDA before doctors can prescribe them. Yet history shows that some of the most serious drug-related injuries, including permanent vision loss, do not come to light until years later.

This pattern is especially important today as lawsuits involving Ozempic and other semaglutide drugs raise concerns about Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), sometimes referred to as an “eye stroke.” Many patients are asking the same question: If this risk is real, why are lawsuits only appearing now?

The answer often comes down to how latent injuries are discovered, how adverse events are reported, and how patterns emerge over time. See more below, and contact New York Ozempic injury lawyer Leandros A. Vrionedes, P.C., if you have been diagnosed with NAION or certain other serious conditions while taking Ozempic or after discontinuing use.

Many Drug Injuries Are “Latent” by Nature

Some drug-related injuries happen immediately. Others develop quietly, without clear warning signs, and may not be diagnosed until months or even years after exposure. Vision loss conditions like NAION fall into this second category.

NAION involves a sudden loss of blood flow to the optic nerve. Affected individuals may wake up one day with blurred vision, dark spots, or partial blindness in one eye. In many cases, the damage is permanent. What makes NAION especially difficult to trace back to a medication is that it often occurs without pain and may look, at first, like a spontaneous medical event rather than a drug-related injury.

When injuries appear suddenly but without an obvious cause, it can take time for doctors and patients to connect the dots. That delay plays a major role in why lawsuits often trail years behind a drug’s release.

Clinical Trials Cannot Catch Every Risk

Before approval, drugs are tested in clinical trials involving a limited number of participants over a limited time. These trials are designed to determine whether a medication is effective and reasonably safe, but they are not large enough or long enough to reveal every possible complication.

Rare but devastating side effects, such as optic nerve damage, may not appear until a drug is used by hundreds of thousands or millions of people in the real world. Certain risks may only affect people with specific health profiles, such as those with diabetes, vascular disease, or blood pressure fluctuations.

As a result, some serious adverse effects only become visible after years of widespread use, once enough cases exist to identify a pattern.

Adverse Event Reporting Often Lags Behind Reality

When patients experience unexpected side effects, those events are supposed to be reported through systems like the FDA’s Adverse Event Reporting System (FAERS). In practice, however, reporting is inconsistent.

Many adverse events go unreported altogether. Others are reported without enough detail to identify a clear link to a specific drug. In some cases, vision loss may be attributed to age, diabetes, or other underlying conditions, rather than investigated as a potential medication-related injury.

Over time, as more reports accumulate and similar injuries are documented, patterns begin to emerge. Only then do researchers, regulators, and plaintiffs’ attorneys start asking whether the manufacturer should have warned users earlier.

Vision Loss Claims Are Especially Slow to Emerge

Vision injuries present unique challenges in drug litigation. Conditions like NAION are relatively rare in the general population, which makes early signals harder to detect. At the same time, the consequences are severe, often permanent, and deeply disruptive to daily life.

Because vision loss can affect employment, independence, and overall quality of life, claims involving blindness or partial blindness tend to be treated as high-severity cases once a potential drug connection is established. That seriousness often drives further investigation and litigation, even if the drug has been on the market for years.

How Ozempic NAION Claims Fit This Pattern

Ozempic was initially approved back in 2017 to treat Type 2 diabetes and later became widely used off-label for weight loss. As its use expanded, reports of severe gastrointestinal and metabolic complications began to surface. More recently, attention has turned to cases of NAION following semaglutide use.

Allegations in these lawsuits focus on whether the manufacturer adequately warned patients and doctors about the risk of optic nerve injury, particularly given the drug’s effects on blood flow, blood pressure, and metabolic regulation. Because NAION is uncommon, its appearance following Ozempic use has raised questions about whether these cases represent a coincidence or something more.

As with many drug injury cases, litigation did not begin the moment the drug was released. Instead, it followed years of use, mounting reports, and growing concern among medical professionals and patients.

Why Legal Action Often Comes “Late”

From a legal standpoint, lawsuits typically begin when three things happen: a patient suffers a serious injury, a possible link to the drug is identified, and there is reason to believe the manufacturer put a dangerous drug on the market or failed to provide adequate warnings.

That process takes time. Patients must first be diagnosed. Doctors must consider potential causes. Researchers must observe trends. Only then do attorneys have enough information to evaluate whether a claim exists.

For individuals who suffer vision loss, this delay can feel frustrating, but it is a common feature of pharmaceutical litigation, not an exception.

Speaking With a Lawyer After Drug-Related Vision Loss

If you or a loved one has experienced sudden or unexplained vision loss after using Ozempic or a similar medication, it is important to understand that your claim is not automatically barred simply because the drug has been on the market for years. In many cases, the law recognizes that injuries involving latent discovery take time to uncover.

At Leandros A. Vrionedes, P.C., we represent individuals throughout Manhattan, Queens, Brooklyn, and the Bronx, as well as Nassau County and Westchester County outside New York City, who have suffered serious injuries due to unsafe drugs and medical products. We closely monitor emerging litigation involving vision loss and other high-impact injuries and can help determine whether a claim may be worth pursuing.

A careful review of medical records, timing, and diagnosis is often the first step toward understanding your legal options. Contact us today for a free consultation.